All Episodes
OncTimes Talk — 100 episodes
Tumor-Specific Immunotherapy for Patients with High-Risk Melanoma: The Potential Role of mRNA Cancer Vaccines
The Future of Cancer Research: Clinical Trials, AI & Access to Care
Targeting Tumor Acidity With Topical Bicarbonate Therapy
Rethinking Breast Cancer Screening
Inside Lytix Biopharma's Breakthrough in Immunotherapy
A Lap Around the Couch: Why Exercise Matters in Cancer Care
Understanding the Rise in Early-Onset Cancer
Championing Community Cancer Care
Radioactive Resilience: A Survivor's Mission to Cure Cancer
Results from OncoExTra® Testing of 10K Tumor Samples Show the Next Generation of Sequencing
The Evolving Landscape of Bladder Cancer
The Current State of Skin Cancer in the U.S.
United Theranostics and the Future of Cancer Care
Smashing Plates, Facing Fear: Heather Von St. James' Journey
Joey-Rose Jester on Life with Cholangiocarcinoma: A Conversation About Cancer, Work, and Everything in Between
From Ironman to Advocate: Tom Hulsey's Journey Through Prostate Cancer and Purpose
Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test
Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield
Defying the Odds: Katie Colman's Journey from Diagnosis to Advocacy
Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing
Patient-Matched Tumor-Normal Sequencing: What It Is and Why It Matters
Transforming colorectal cancer management with tumor informed ctDNA testing
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk
Episode 3, Better Informed Patient Journeys
Episode 2, HRD Testing Deep-Dive
Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer
Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development
Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma
Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer
The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front
Digital Twin Brings AI Power to Individualize Cancer Management
Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma
Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers
FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer
Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors
Antibody-Drug Conjugate "Promising Efficacy" in HER2-Positive and HER2-Low Breast Cancer
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer
ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology's Globally Upscale 2024 Annual Meeting
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies
HPV Vaccination Prevents HIV-Related Cancers in Men
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
Exercise Deters Prostate Cancer Death & Progression
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
Important Mantle Cell Lymphoma Findings From the Sympatico Study
World's Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
INTERLACE Study Boosts Cervical Cancer Survival
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations